Citi Reiterates Sell Rating on PTC Therapeutics (PTCT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
PTC Therapeutics (PTCT) Announces FDA Target Regulatory Action Date of July 29, 2025 for Sepiapterin and Lancet Publication of Phase 3 Trial Results
October 14, 2024 4:30 PM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New Drug Application (NDA) for sepiapterin, consistent with a standard review timeline. The NDA was submitted with an indication for the treatment of pediatric and... More
PTC Therapeutics (PTCT) PT Raised to $45 at Morgan Stanley
October 11, 2024 8:24 AM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $32.00) while maintaining a Equalweight rating.... More
